First Tracks BiotherapeuticsTRAX +11.85%12 Quick Ratio is 10.78 as of Dec. 2024, which is 34% below its 10-year median of 16.33. GuruFocus rates TRAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, First Tracks Biotherapeutics ranks better than 80.65% on this metric.
First Tracks Biotherapeutics has a quick ratio of 10.78. It generally indicates good short-term financial strength.
The historical rank and industry rank for First Tracks Biotherapeutics's Quick Ratio or its related term are showing as below:
TRAX'
s Quick Ratio Range Over the Past 10 Years
Min: 10.78 Med: 16.33 Max: 21.87
Current: 10.78
During the past 2 years, First Tracks Biotherapeutics's highest Quick Ratio was 21.87. The lowest was 10.78. And the median was 16.33.
TRAX's Quick Ratio is ranked better than 80.65% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs TRAX: 10.78
First Tracks Biotherapeutics (NAS:TRAX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
First Tracks Biotherapeutics Quick Ratio Related Terms
First Tracks Biotherapeutics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
First Tracks Biotherapeutics Quick Ratio Chart
First Tracks Biotherapeutics Annual Data
Trend
Dec23
Dec24
Quick Ratio
21.87
10.78
First Tracks Biotherapeutics Semi-Annual Data
Dec23
Dec24
Quick Ratio
21.87
10.78
TRAX vs ALT, RGNX, MDXG: Quick Ratio Comparison
For the Biotechnology subindustry, First Tracks Biotherapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
First Tracks Biotherapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where First Tracks Biotherapeutics's Quick Ratio falls into.
First Tracks Biotherapeutics Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
First Tracks Biotherapeutics (TRAX) has a Quick Ratio of 10.78 as of Dec. 2024. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on First Tracks Biotherapeutics and its competitors. This is 34% below median its historical median of 16.33. Over the past decade, First Tracks Biotherapeutics' Quick Ratio has ranged from 10.78 to 21.87. According to the industry distribution chart, First Tracks Biotherapeutics ranks #273 out of 1411 companies in the Biotechnology industry, placing it in the top 19.3%.
Is First Tracks Biotherapeutics' Quick Ratio too high?
First Tracks Biotherapeutics' current Quick Ratio of 10.78 is 34% below median its 10-year median of 16.33. Over the past 10 years, this metric has ranged from a low of 10.78 to a high of 21.87. The Biotechnology industry median Quick Ratio is 3.59. First Tracks Biotherapeutics' value of 10.78 is 200.3% above this industry median. Based on the distribution chart, First Tracks Biotherapeutics ranks #273 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Quick Ratio compare to ALT and RGNX?
According to the Biotechnology industry distribution chart, First Tracks Biotherapeutics ranks #273 out of 1411 companies for Quick Ratio. This places First Tracks Biotherapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.59. First Tracks Biotherapeutics' value of 10.78 is 200.3% above this benchmark. Historically, First Tracks Biotherapeutics' own Quick Ratio has ranged from 10.78 to 21.87 over the past decade. While the company's 10-year median is 16.33 vs. the industry median of 3.59, First Tracks Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. First Tracks Biotherapeutics's current Quick Ratio of 10.78 is 200.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on First Tracks Biotherapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. First Tracks Biotherapeutics's current Quick Ratio is 10.78, which is 34% below median its own 10-year median of 16.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current Quick Ratio of 10.78. The current Quick Ratio is 10.78, which is 34% below median its 10-year median of 16.33 and 200.3% above the Biotechnology industry median of 3.59. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current Quick Ratio is 10.78 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score
Get the complete analysis for TRAX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRAX has been successfully added to your 